Related Experiment Video
Updated: Mar 6, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
6.1K
Does percutaneous coronary stent implantation increase platelet reactivity?
P W A Janssen1, E A Mol2, S M C Geene1
1Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; St. Antonius Center for Platelet Function Research, St. Antonius Hospital, Nieuwegein, The Netherlands.
Blood Reviews
|March 18, 2017
Summary
High platelet reactivity (PR) measurements after percutaneous coronary intervention (PCI) may be affected by stent implantation. Optimal timing for PR assessment is crucial for accurate antiplatelet therapy response and thrombotic event risk prediction.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Background:
- High platelet reactivity (PR) on clopidogrel therapy correlates with thrombotic events post-percutaneous coronary intervention (PCI).
- The optimal timing for PR measurement (pre-PCI vs. post-PCI) remains unclear.
- PCI procedures, including stent implantation, may acutely affect platelet activation and reactivity.
Purpose of the Study:
- To evaluate the impact of stent implantation during PCI on PR.
- To determine the optimal timing for PR measurements in patients undergoing PCI.
- To improve the interpretation of antiplatelet therapy response and thrombotic risk prediction.
Main Methods:
- Systematic literature search was conducted.
- Studies investigating PR in patients undergoing PCI were reviewed.
- Data on PR changes related to PCI timing were analyzed.
Main Results:
- Stent implantation during PCI may influence PR measurements.
- Timing of PR assessment (before vs. after PCI) can affect reported reactivity levels.
- Variability in PR measurements can impact clinical decision-making.
Conclusions:
- The timing of PR measurement is critical for accurate assessment of antiplatelet therapy effectiveness post-PCI.
- Further research is needed to establish standardized protocols for PR testing.
- Optimizing PR measurement timing can enhance patient risk stratification and management.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:27Peripheral Artery Disease III: Interprofessional Care
457
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
457
01:22Formation of the Platelet Plug
10.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.2K
01:27Coronary Artery Disease V: Interprofessional Care
352
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
352
01:28Acute Coronary Syndrome IV: Interprofessional Care
356
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
356
01:30Acute Coronary Syndrome I: Introduction
1.3K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K